Skip to content
← All treatment topics

TREATMENT READING

Hypopharyngeal Cancer

Source sections for this topic, with the original link and date. Patient and professional reading are labelled separately.

Not medical advice · Not a complete treatment or trial directory

Made by Triangle.

Selected text from the National Cancer Institute, with the original link and date. Made by Triangle. This page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.

40 sections
  1. Treatment Option Overview for Hypopharyngeal Cancer
  2. Treatment Overview
  3. Fluorouracil Dosing
  4. Treatment of Stage I Hypopharyngeal Cancer
  5. Treatment Options for Stage I Hypopharyngeal Cancer
  6. Treatment of Stage II Hypopharyngeal Cancer
  7. Treatment Options for Stage II Hypopharyngeal Cancer
  8. Treatment of Stage III Hypopharyngeal Cancer
  9. Treatment Options for Stage III Hypopharyngeal Cancer
  10. Treatment of Stage IV Hypopharyngeal Cancer
  11. Treatment Options for Resectable Stage IV Hypopharyngeal Cancer
  12. Treatment Options for Unresectable Stage IV Hypopharyngeal Cancer
  13. Posttreatment follow-up for unresectable stage IV hypopharyngeal cancer
  14. Treatment of Metastatic and Recurrent Hypopharyngeal Cancer
  15. Treatment Options for Metastatic and Recurrent Hypopharyngeal Cancer
  16. Immunotherapy
  17. Pembrolizumab
  18. Nivolumab
  19. Posttreatment follow-up for metastatic and recurrent hypopharyngeal cancer
  20. Certain factors affect prognosis (chance of recovery) and treatment options.
  21. After surgery, the stage of the cancer may change and more treatment may be needed.
  22. Hypopharyngeal cancer can recur (come back) after it has been treated.
  23. Treatment Option Overview
  24. Key Points
  25. There are different types of treatment for patients with hypopharyngeal cancer.
  26. The following types of treatment are used:
  27. Surgery
  28. Radiation therapy
  29. Chemotherapy
  30. Immunotherapy
  31. New types of treatment are being tested in clinical trials.
  32. Treatment for hypopharyngeal cancer may cause side effects.
  33. Patients may want to think about taking part in a clinical trial.
  34. Patients can enter clinical trials before, during, or after starting their cancer treatment.
  35. Follow-up care may be needed.
  36. Treatment of Stage I Hypopharyngeal Cancer
  37. Treatment of Stage II Hypopharyngeal Cancer
  38. Treatment of Stage III Hypopharyngeal Cancer
  39. Treatment of Stage IV Hypopharyngeal Cancer
  40. Treatment of Recurrent and Metastatic Hypopharyngeal Cancer

Health professional

Treatment Option Overview for Hypopharyngeal Cancer

Source: Hypopharyngeal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 14, 2025. Captured 2026-09-09.

Hypopharyngeal cancer usually does not cause symptoms until late in the course of the disease. Coupled with the high incidence of early metastasis, survival rates for carcinoma of the hypopharynx are perhaps the lowest of all cancer sites in the head and neck.

No single therapeutic regimen offers a superior survival advantage over other regimens. Although the literature highlights various therapeutic options, few reports present any valid comparative studies. The ultimate therapeutic choice will depend on a careful review of each individual case, paying attention to the staging of the neoplasm, the patient's general physical condition and emotional status, the experience of the treating team, and the available treatment facilities.[1,2]

Sources: 1 · 2

This page is made by Triangle. The reading above is selected source text, not a treatment recommendation, and it is not medical advice.

Health professional · Treatment Option Overview for Hypopharyngeal Cancer

Treatment Overview

Source: Hypopharyngeal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 14, 2025. Captured 2026-09-09.

Except for very early stage (T1) cancers of this region, treatment has primarily been surgery, usually followed with postoperative radiation therapy (PORT). Some early stage (T1 and T2), low-volume, exophytic pyriform sinus carcinomas have been successfully treated with radiation therapy alone.[3-5] Single-modality therapy of advanced-stage hypopharyngeal cancer, with either surgery or radiation therapy, has resulted in consistently poor survival.[6-8]

Sources: 3 · 5 · 6 · 8

Combined-modality treatment should be considered for patients with stage III or stage IV disease.[4,6,9,10] When used with surgery, radiation therapy is typically administered postoperatively. In selected advanced cases, alternative strategies using neoadjuvant chemotherapy and radiation therapy may increase the chance for local control as much as resection and PORT.[4]

Sources: 4 · 6 · 9 · 10 · 4

A review of published clinical results of radical radiation therapy for head and neck cancer suggests a significant loss of local control when radiation therapy was prolonged; therefore, lengthening of standard treatment schedules should be avoided whenever possible.[11,12]

Sources: 11 · 12

Chronic pulmonary and hepatic diseases related to excessive tobacco and alcohol use are common in patients with head and neck cancer; recognition of these comorbidities is essential when planning appropriate treatment.[6] Patients who smoke during radiation therapy appear to have lower response rates and shorter survival durations than those who do not.[13] Consequently, patients should be counseled to stop smoking before beginning radiation therapy. Evidence has demonstrated a high incidence (i.e., >30%–40%) of hypothyroidism in patients who have received external-beam radiation therapy to the entire thyroid gland or to the pituitary gland. Thyroid function testing of patients should be considered before therapy and as part of posttreatment follow-up.[14,15]

Sources: 6 · 13 · 14 · 15

Health professional · Treatment Option Overview for Hypopharyngeal Cancer

Fluorouracil Dosing

Source: Hypopharyngeal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 14, 2025. Captured 2026-09-09.

The DPYD gene encodes an enzyme that catabolizes pyrimidines and fluoropyrimidines, like capecitabine and fluorouracil. An estimated 1% to 2% of the population has germline pathogenic variants in DPYD, which lead to reduced DPD protein function and an accumulation of pyrimidines and fluoropyrimidines in the body.[16,17] Patients with the DPYD*2A variant who receive fluoropyrimidines may experience severe, life-threatening toxicities that are sometimes fatal. Many other DPYD variants have been identified, with a range of clinical effects.[16-18] Fluoropyrimidine avoidance or a dose reduction of 50% may be recommended based on the patient's DPYD genotype and number of functioning DPYD alleles.[19-21] DPYD genetic testing costs less than $200, but insurance coverage varies due to a lack of national guidelines.[22] In addition, testing may delay therapy by 2 weeks, which would not be advisable in urgent situations. This controversial issue requires further evaluation.[23]

Sources: 16 · 17 · 16 · 18 · 19 · 21 · 22 · 23

Health professional

Treatment of Stage I Hypopharyngeal Cancer

Source: Hypopharyngeal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 14, 2025. Captured 2026-09-09.

Health professional · Treatment of Stage I Hypopharyngeal Cancer

Treatment Options for Stage I Hypopharyngeal Cancer

Source: Hypopharyngeal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 14, 2025. Captured 2026-09-09.

Except for the very early T1 cancers of this region, treatment has been primarily surgery, usually followed with postoperative radiation therapy. Because these tumors are clinically silent until they reach advanced stages, it is very unusual to diagnose them at the T1 N0 stage. In most available retrospective reviews, T1 N0 cases represent only 1% to 2% of all patients seen. In the case of exophytic T1 N0 lesions, radiation therapy alone may be considered.[1,2]

Sources: 1 · 2

Treatment options for stage I hypopharyngeal cancer include:

Laryngopharyngectomy and neck dissection has been the most frequently used therapy for hypopharyngeal cancers.In very selected cases of pyriform sinus cancers, that is, those arising in the upper lateral wall, a partial laryngopharyngectomy may be successfully used to preserve vocal function. All groups who use radiation therapy advocate high-dose treatment to the primary site and to both sides of the neck to include the retropharyngeal and lateral cervical nodes.[1]

Sources: 1

Health professional

Treatment of Stage II Hypopharyngeal Cancer

Source: Hypopharyngeal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 14, 2025. Captured 2026-09-09.

Health professional · Treatment of Stage II Hypopharyngeal Cancer

Treatment Options for Stage II Hypopharyngeal Cancer

Source: Hypopharyngeal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 14, 2025. Captured 2026-09-09.

Treatment has been primarily surgery, which is usually followed with postoperative radiation therapy (PORT). Because these tumors are clinically silent until they reach advanced stages, it is very unusual to diagnose these tumors at the T2 N0 stage.

Treatment options for stage II hypopharyngeal cancer include:

Laryngopharyngectomy and neck dissection has been the most frequently used therapy for hypopharyngeal cancers.In very selected cases of pyriform sinus cancers, that is, those arising in the upper medial wall, a partial laryngopharyngectomy may be successfully used to preserve vocal function. In T2 cases, PORT has been given in combination with surgery in an effort to improve the local control rates of surgery alone. There are advocates of preoperative radiation therapy, but all groups giving radiation therapy advocate high-dose treatment to the primary site and to both sides of the neck to include the retropharyngeal and lateral cervical nodes.[1,2]

Sources: 1 · 2

Neoadjuvant chemotherapy is commonly used to treat patients who present with advanced disease to improve locoregional control or survival, despite the lack of data from randomized, prospective trials.[3]The use of neoadjuvant chemotherapy to increase organ preservation has also been advocated. In a prospective randomized trial (GORTEC-TREMPLIN trial [NCT00169247]), the European Organisation for the Research and Treatment of Cancer compared surgery plus PORT with neoadjuvant chemotherapy (i.e., cisplatin plus fluorouracil) followed by radiation therapy in responding patients. Local and regional failures were similar in both groups. Although median survival was 25 months in the immediate surgery arm of the study and 44 months in the induction chemotherapy arm (P = .006), 5-year disease-free and overall survival were the same. A functional larynx was preserved in 42% of patients at 3 years and 35% at 5 years in patients who received induction chemotherapy. These data have not been confirmed by other phase III trials but suggest that larynx preservation may be feasible without jeopardizing survival.[4][Level of evidence A1 and A3]Most neoadjuvant chemotherapy clinical trials have included patients with stage II hypopharyngeal carcinoma because of the low survival rates for this population.[5]

Sources: 3 · GORTEC-TREMPLIN · 4 · A1 · A3 · 5

Health professional

Treatment of Stage III Hypopharyngeal Cancer

Source: Hypopharyngeal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 14, 2025. Captured 2026-09-09.

Health professional · Treatment of Stage III Hypopharyngeal Cancer

Treatment Options for Stage III Hypopharyngeal Cancer

Source: Hypopharyngeal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 14, 2025. Captured 2026-09-09.

The management of patients with stage III hypopharyngeal cancer is complex and requires multidisciplinary input to establish the optimal treatment regimen. New surgical techniques and reconstructions (using the gastric pull-up operation or free jejunal transfers) have greatly reduced the morbidity associated with resection of these tumors and have almost eliminated the need for multistage reconstructions. This has greatly aided the combined treatment regimens because these patients have a high likelihood of beginning postoperative radiation therapy (PORT) within 3 to 4 weeks following resection.

Details of surgical procedures and modifications of radiation fields or dosage schedules are not specifically designated here because of legitimate variations in techniques that, according to various retrospective data, give similar survival results in different treatment centers. This group of patients should be managed by surgeons and radiation oncologists who are skilled in the multiple procedures and techniques available, and who are actively and frequently involved in the care of these patients.

Treatment options for stage III hypopharyngeal cancer include:

The combination of surgery and radiation, most often postoperative as seen in a follow-up study of preoperative versus PORT (RTOG-7303), has become the usual form of therapy for this group of patients in the United States.[1-3]

Sources: 1 · 3

Neoadjuvant chemotherapy is commonly used to treat patients who present with advanced disease to improve locoregional control or survival, despite the lack of data from randomized prospective trials.[4]The use of neoadjuvant chemotherapy to increase organ preservation has also been advocated. In a prospective randomized trial (GORTEC-TREMPLIN [NCT00169247]), the European Organisation for the Treatment and Research of Cancer compared surgery plus PORT with induction chemotherapy (i.e., cisplatin plus fluorouracil [5-FU]) followed by radiation in responding patients.[5] Local and regional failures were similar in both groups. Although median survival was 25 months in the immediate surgery arm of the study and 44 months in the induction chemotherapy arm (P = .006), 5-year disease-free survival (DFS) and overall survival (OS) were the same. A functional larynx was preserved in 42% of patients at 3 years and 35% at 5 years in patients who received induction chemotherapy.[5][Level of evidence A1 and A3]In contrast to this, another randomized prospective trial has demonstrated a statistically significant survival advantage for patients undergoing chemotherapy (i.e., cisplatin plus 5-FU) followed by laryngopharyngectomy and PORT when compared with chemotherapy and radiation therapy.[6][Level of evidence A1 and A3] Although organ preservation was not discussed in this study, chemotherapy in combination with radiation therapy without surgery should not be considered standard treatment.

Sources: 4 · GORTEC-TREMPLIN · 5 · 5 · A1 · A3 · 6 · A1 · A3

Patients with stage III hypopharyngeal cancer should consider combined postoperative, adjuvant radiation therapy and chemotherapy. In a prospective randomized trial, postoperative adjuvant radiation therapy alone was compared with postoperative adjuvant radiation therapy plus concurrent chemotherapy. Both the OS (P < .01) and the DFS (P < .02) were better in the group of patients receiving radiation therapy plus concurrent chemotherapy.[7][Level of evidence A1] In another study, primary site preservation was improved, though OS was not improved when chemotherapy was administered concomitantly with radiation therapy.[8,9]

Sources: 7 · Level of evidence A1 · 8 · 9

Chemotherapy combined with radiation therapy for patients with locally advanced disease (under clinical evaluation).[10-12] Concurrent chemotherapy is a standard treatment option for patients with locally advanced (stage III and stage IV) hypopharyngeal cancer. A meta-analysis of 93 randomized prospective head and neck cancer trials published between 1965 and 2000 showed a 4.5% absolute survival advantage in the subset of patients who received chemotherapy and radiation therapy.[13][Level of evidence B4] Patients who received concurrent chemotherapy had a greater survival benefit than those who received induction chemotherapy.

Sources: 10 · 12 · 13 · Level of evidence B4

For more information about treatment options for stage III hypopharyngeal cancer, see the Treatment Options for Unresectable Stage IV Hypopharyngeal Cancer section.

Sources: Treatment Options for Unresectable Stage IV Hypopharyngeal Cancer

Health professional

Treatment of Stage IV Hypopharyngeal Cancer

Source: Hypopharyngeal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 14, 2025. Captured 2026-09-09.

Health professional · Treatment of Stage IV Hypopharyngeal Cancer

Treatment Options for Resectable Stage IV Hypopharyngeal Cancer

Source: Hypopharyngeal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 14, 2025. Captured 2026-09-09.

The management of patients with resectable hypopharyngeal cancer is complex and requires multidisciplinary input to establish the optimal treatment regimen. New surgical techniques and reconstructions using the gastric pull-up operation or free jejunal transfers have greatly reduced the morbidity associated with resection of these tumors and have almost eliminated the need for multistage reconstructions. This has greatly aided the combined treatment regimens because these patients have a high likelihood of beginning postoperative radiation therapy within 3 to 4 weeks following resection.

Details of surgical procedures and modifications of radiation fields or dosage schedules are not specifically designated here because of legitimate variations in techniques that, according to various retrospective data, give similar survival results in different treatment centers. This group of patients should be managed by surgeons and radiation oncologists who are skilled in the multiple procedures and techniques available, and who are actively and frequently involved in the care of these patients.

Treatment options for resectable stage IV hypopharyngeal cancer include:

The combination of surgery and radiation, most often postoperative as seen in a follow-up study of preoperative versus postoperative radiation therapy (PORT) (RTOG-7303), has become the usual form of therapy for this group of patients in the United States.[1,2]

Sources: 1 · 2

Neoadjuvant chemotherapy is commonly used to treat patients presenting with advanced disease to improve locoregional control or survival, despite the lack of data from randomized prospective trials.[3] The use of neoadjuvant chemotherapy to increase organ preservation has also been advocated. In a prospective randomized trial (GORTEC-TREMPLIN [NCT00169247]), the European Organisation for the Research and Treatment of Cancer compared surgery plus PORT with induction chemotherapy (i.e., cisplatin plus fluorouracil [5-FU]) followed by radiation in responding patients.[4] Local and regional failures were similar in both groups. Although median survival was 25 months in the immediate surgery arm of the study and 44 months in the induction chemotherapy arm (P = .006), 5-year disease-free survival (DFS) and overall survival (OS) were the same. A functional larynx was preserved in 42% of patients at 3 years and 35% at 5 years in patients who received induction chemotherapy.[4][Level of evidence A1 and A3]In contrast to this, another randomized prospective trial has demonstrated a statistically significant survival advantage for patients undergoing chemotherapy (i.e., cisplatin plus 5-FU) followed by laryngopharyngectomy and PORT when compared with chemotherapy and radiation therapy.[5][Level of evidence A1 and A3] Although organ preservation was not discussed, chemotherapy in combination with radiation therapy without surgery should not be considered standard treatment.

Sources: 3 · GORTEC-TREMPLIN · 4 · 4 · A1 · A3 · 5 · A1 · A3

Patients with stage IV hypopharyngeal cancer should consider combined postoperative, adjuvant radiation therapy and chemotherapy. In a prospective randomized trial, postoperative adjuvant radiation therapy alone was compared with postoperative adjuvant radiation therapy plus concurrent chemotherapy. Both the OS (P < .01) and the DFS (P < .02) were better in the group of patients who received radiation therapy plus concurrent chemotherapy.[6][Level of evidence A1] In another study, primary site preservation was improved, though OS was not improved when chemotherapy was given concomitantly with radiation therapy.[7,8]

Sources: 6 · Level of evidence A1 · 7 · 8

Health professional · Treatment of Stage IV Hypopharyngeal Cancer

Treatment Options for Unresectable Stage IV Hypopharyngeal Cancer

Source: Hypopharyngeal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 14, 2025. Captured 2026-09-09.

Treatment options for unresectable stage IV hypopharyngeal cancer include:

Radiation therapy.

Chemotherapy has been combined with radiation therapy in patients who have locally advanced disease.[9-11] In a randomized trial, the 3-year projected OS rate was 37% (P = .14) for patients with stage III or stage IV inoperable disease receiving single daily fractionated radiation with concurrent cisplatin.[11][Level of evidence A1]

Sources: 9 · 11 · 11 · Level of evidence A1

Radiation therapy clinical trials evaluating hyperfractionation schedules may be considered with chemotherapy (under clinical evaluation).[12-17] Concurrent chemotherapy is a standard treatment option for patients with locally advanced (stage III and stage IV) hypopharyngeal cancer. A meta-analysis of 93 randomized prospective head and neck cancer trials published between 1965 and 2000 showed a 4.5% absolute survival advantage in the subset of patients who received chemotherapy and radiation therapy.[18][Level of evidence B4] Patients who received concurrent chemotherapy had a greater survival benefit than those who received induction chemotherapy.

Sources: 12 · 17 · 18 · Level of evidence B4

Health professional · Treatment of Stage IV Hypopharyngeal Cancer / Treatment Options for Unresectable Stage IV Hypopharyngeal Cancer

Posttreatment follow-up for unresectable stage IV hypopharyngeal cancer

Source: Hypopharyngeal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 14, 2025. Captured 2026-09-09.

These patients should have a careful head and neck examination, looking for recurrence monthly for the first posttreatment year, every 2 months for the second year, every 3 months the third year, and every 6 months thereafter.

Health professional

Treatment of Metastatic and Recurrent Hypopharyngeal Cancer

Source: Hypopharyngeal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 14, 2025. Captured 2026-09-09.

Health professional · Treatment of Metastatic and Recurrent Hypopharyngeal Cancer

Treatment Options for Metastatic and Recurrent Hypopharyngeal Cancer

Source: Hypopharyngeal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 14, 2025. Captured 2026-09-09.

Treatment options for metastatic and recurrent hypopharyngeal cancer include:

Surgical resection if radiation therapy fails and if technically feasible.[1]

Sources: 1

Radiation therapy, if not previously used in curative doses that preclude further treatment, if surgery fails.

Surgical salvage, if technically feasible, when surgery fails.

Chemotherapy for metastatic disease.[2]

Sources: 2

Immunotherapy.[3-11]

Sources: Immunotherapy · 3 · 11

Immunotherapy.[3-11]

Pembrolizumab.

Sources: Pembrolizumab

Nivolumab.

Sources: Nivolumab

Clinical trials evaluating the use of chemotherapy should be considered.[12]

Sources: 12

Health professional · Treatment of Metastatic and Recurrent Hypopharyngeal Cancer / Treatment Options for Metastatic and Recurrent Hypopharyngeal Cancer

Immunotherapy

Source: Hypopharyngeal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 14, 2025. Captured 2026-09-09.

Health professional · Treatment of Metastatic and Recurrent Hypopharyngeal Cancer / Treatment Options for Metastatic and Recurrent Hypopharyngeal Cancer / Immunotherapy

Pembrolizumab

Source: Hypopharyngeal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 14, 2025. Captured 2026-09-09.

Pembrolizumab is a monoclonal antibody and an inhibitor of the programmed death-1 (PD-1) pathway. Studies have evaluated pembrolizumab in patients with incurable metastatic or recurrent head and neck squamous cell carcinoma (SCC).

Evidence (pembrolizumab as first-line therapy):

KEYNOTE-048 (NCT02358031) was a nonblinded, randomized, phase III study of participants with untreated locally incurable metastatic or recurrent head and neck SCC that was performed at 200 sites in 37 countries.[3] A total of 882 patients were randomly assigned in a 1:1:1 ratio to receive pembrolizumab alone (n = 301), pembrolizumab plus a platinum and fluorouracil (5-FU) (pembrolizumab with chemotherapy) (n = 281), or cetuximab plus a platinum and 5-FU (cetuximab with chemotherapy) (n = 300). Investigators, patients, and representatives of the sponsor were masked to the programmed death-ligand 1 (PD-L1) combined positive score (CPS) results; PD-L1 positivity was not required for study entry. A total of 754 patients (85%) had a CPS of 1 or higher and 381 patients (43%) had a CPS of 20 or higher.The primary end points were overall survival (OS) and progression-free survival (PFS). Progression was defined as radiographically confirmed disease progression or death from any cause, whichever came first, in the intention-to-treat population.

Sources: KEYNOTE-048 · 3

KEYNOTE-048 (NCT02358031) was a nonblinded, randomized, phase III study of participants with untreated locally incurable metastatic or recurrent head and neck SCC that was performed at 200 sites in 37 countries.[3] A total of 882 patients were randomly assigned in a 1:1:1 ratio to receive pembrolizumab alone (n = 301), pembrolizumab plus a platinum and fluorouracil (5-FU) (pembrolizumab with chemotherapy) (n = 281), or cetuximab plus a platinum and 5-FU (cetuximab with chemotherapy) (n = 300). Investigators, patients, and representatives of the sponsor were masked to the programmed death-ligand 1 (PD-L1) combined positive score (CPS) results; PD-L1 positivity was not required for study entry. A total of 754 patients (85%) had a CPS of 1 or higher and 381 patients (43%) had a CPS of 20 or higher.The primary end points were overall survival (OS) and progression-free survival (PFS). Progression was defined as radiographically confirmed disease progression or death from any cause, whichever came first, in the intention-to-treat population.

At the second interim analysis, pembrolizumab alone showed improved or noninferior OS compared with cetuximab with chemotherapy. The median OS results were reported as follows:[3][Level of evidence A1]

Sources: 3 · Level of evidence A1

KEYNOTE-048 (NCT02358031) was a nonblinded, randomized, phase III study of participants with untreated locally incurable metastatic or recurrent head and neck SCC that was performed at 200 sites in 37 countries.[3] A total of 882 patients were randomly assigned in a 1:1:1 ratio to receive pembrolizumab alone (n = 301), pembrolizumab plus a platinum and fluorouracil (5-FU) (pembrolizumab with chemotherapy) (n = 281), or cetuximab plus a platinum and 5-FU (cetuximab with chemotherapy) (n = 300). Investigators, patients, and representatives of the sponsor were masked to the programmed death-ligand 1 (PD-L1) combined positive score (CPS) results; PD-L1 positivity was not required for study entry. A total of 754 patients (85%) had a CPS of 1 or higher and 381 patients (43%) had a CPS of 20 or higher.The primary end points were overall survival (OS) and progression-free survival (PFS). Progression was defined as radiographically confirmed disease progression or death from any cause, whichever came first, in the intention-to-treat population. › At the second interim analysis, pembrolizumab alone showed improved or noninferior OS compared with cetuximab with chemotherapy. The median OS results were reported as follows:[3][Level of evidence A1]

Among the population with a CPS of 20 or higher, the median OS was 14.9 months in patients who received pembrolizumab alone and 10.7 months in patients who received cetuximab with chemotherapy (hazard ratio [HR], 0.61; 95% confidence interval [CI], 0.45–0.83; P = .0007).

Among the population with a CPS of 1 or higher, the median OS was 12.3 months in patients who received pembrolizumab alone and 10.3 months in patients who received cetuximab with chemotherapy (HR, 0.78; 95% CI, 0.64–0.96; P = .0086).

Among the total population, patients who received pembrolizumab alone had noninferior OS (11.6 months) compared with patients who received cetuximab with chemotherapy (10.7 months) (HR, 0.85; 95% CI, 0.71–1.03; P = .0456).

KEYNOTE-048 (NCT02358031) was a nonblinded, randomized, phase III study of participants with untreated locally incurable metastatic or recurrent head and neck SCC that was performed at 200 sites in 37 countries.[3] A total of 882 patients were randomly assigned in a 1:1:1 ratio to receive pembrolizumab alone (n = 301), pembrolizumab plus a platinum and fluorouracil (5-FU) (pembrolizumab with chemotherapy) (n = 281), or cetuximab plus a platinum and 5-FU (cetuximab with chemotherapy) (n = 300). Investigators, patients, and representatives of the sponsor were masked to the programmed death-ligand 1 (PD-L1) combined positive score (CPS) results; PD-L1 positivity was not required for study entry. A total of 754 patients (85%) had a CPS of 1 or higher and 381 patients (43%) had a CPS of 20 or higher.The primary end points were overall survival (OS) and progression-free survival (PFS). Progression was defined as radiographically confirmed disease progression or death from any cause, whichever came first, in the intention-to-treat population.

Pembrolizumab with chemotherapy showed improved OS versus cetuximab with chemotherapy. The OS results were reported as follows:

KEYNOTE-048 (NCT02358031) was a nonblinded, randomized, phase III study of participants with untreated locally incurable metastatic or recurrent head and neck SCC that was performed at 200 sites in 37 countries.[3] A total of 882 patients were randomly assigned in a 1:1:1 ratio to receive pembrolizumab alone (n = 301), pembrolizumab plus a platinum and fluorouracil (5-FU) (pembrolizumab with chemotherapy) (n = 281), or cetuximab plus a platinum and 5-FU (cetuximab with chemotherapy) (n = 300). Investigators, patients, and representatives of the sponsor were masked to the programmed death-ligand 1 (PD-L1) combined positive score (CPS) results; PD-L1 positivity was not required for study entry. A total of 754 patients (85%) had a CPS of 1 or higher and 381 patients (43%) had a CPS of 20 or higher.The primary end points were overall survival (OS) and progression-free survival (PFS). Progression was defined as radiographically confirmed disease progression or death from any cause, whichever came first, in the intention-to-treat population. › Pembrolizumab with chemotherapy showed improved OS versus cetuximab with chemotherapy. The OS results were reported as follows:

At the second interim analysis, among the total population, the median OS was 13.0 months in patients who received pembrolizumab with chemotherapy and 10.7 months in patients who received cetuximab with chemotherapy (HR, 0.77; 95% CI, 0.63–0.93; P = .0034).

At the final analysis, among the population with a CPS of 20 or higher, the median OS was 14.7 months in patients who received pembrolizumab with chemotherapy and 11.0 months in patients who received cetuximab with chemotherapy (HR, 0.60; 95% CI, 0.45–0.82; P = .0004).

At the final analysis, among the population with a CPS of 1 or higher, the median OS was 13.6 months in patients who received pembrolizumab with chemotherapy and 10.4 months in patients who received cetuximab with chemotherapy (HR, 0.65; 95% CI, 0.53–0.80; P < .0001).

KEYNOTE-048 (NCT02358031) was a nonblinded, randomized, phase III study of participants with untreated locally incurable metastatic or recurrent head and neck SCC that was performed at 200 sites in 37 countries.[3] A total of 882 patients were randomly assigned in a 1:1:1 ratio to receive pembrolizumab alone (n = 301), pembrolizumab plus a platinum and fluorouracil (5-FU) (pembrolizumab with chemotherapy) (n = 281), or cetuximab plus a platinum and 5-FU (cetuximab with chemotherapy) (n = 300). Investigators, patients, and representatives of the sponsor were masked to the programmed death-ligand 1 (PD-L1) combined positive score (CPS) results; PD-L1 positivity was not required for study entry. A total of 754 patients (85%) had a CPS of 1 or higher and 381 patients (43%) had a CPS of 20 or higher.The primary end points were overall survival (OS) and progression-free survival (PFS). Progression was defined as radiographically confirmed disease progression or death from any cause, whichever came first, in the intention-to-treat population.

At the second interim analysis, neither pembrolizumab alone nor pembrolizumab with chemotherapy improved PFS.

At the final analysis, grade 3 or higher all-cause adverse events occurred in 164 of 300 patients (55%) in the pembrolizumab-alone group, 235 of 276 patients (85%) who received pembrolizumab with chemotherapy, and 239 of 287 patients (83%) who received cetuximab with chemotherapy.

Adverse events led to death in 25 patients (8%) in the pembrolizumab-alone group, 32 patients (12%) who received pembrolizumab with chemotherapy, and 28 patients (10%) who received cetuximab with chemotherapy.

Pembrolizumab plus a platinum and 5-FU is an appropriate first-line treatment for patients with metastatic or recurrent head and neck SCC. Pembrolizumab monotherapy is an appropriate first-line treatment for patients with PD-L1–positive metastatic or recurrent head and neck SCC. These results were confirmed at a longer median follow-up of 45 months (interquartile range, 41.0–49.2).[9]

Sources: 9

Evidence (pembrolizumab after progression on platinum-based treatment):

The phase III KEYNOTE-040 (NCT02252042) trial included patients with incurable metastatic or recurrent head and neck SCC who had received platinum-based treatment within 3 to 6 months.[4] Patients were randomly assigned to the pembrolizumab arm (200 mg every 3 weeks [247 patients]) or to the standard therapy arm of the investigator’s choice (methotrexate, docetaxel, or cetuximab [248 patients]). Patients received treatment until progression or toxicity. The maximum duration of pembrolizumab was 24 months. The primary end point was OS in the intention-to-treat population.

Sources: KEYNOTE-040 · 4

The phase III KEYNOTE-040 (NCT02252042) trial included patients with incurable metastatic or recurrent head and neck SCC who had received platinum-based treatment within 3 to 6 months.[4] Patients were randomly assigned to the pembrolizumab arm (200 mg every 3 weeks [247 patients]) or to the standard therapy arm of the investigator’s choice (methotrexate, docetaxel, or cetuximab [248 patients]). Patients received treatment until progression or toxicity. The maximum duration of pembrolizumab was 24 months. The primary end point was OS in the intention-to-treat population.

The median OS was 8.4 months in the pembrolizumab arm and 6.9 months in the standard therapy arm (HR, 0.80; 95% CI, 0.65–0.98; nominal P = .0161).[4][Level of evidence A1]

Sources: 4 · Level of evidence A1

Pembrolizumab was associated with fewer grade 3 or higher adverse events (pembrolizumab, 13% vs. standard therapy, 36%). The most common treatment-related adverse events were hypothyroidism (13%) in the pembrolizumab arm and fatigue (18%) in the standard therapy arm.

In patients who received pembrolizumab, there were four treatment-related deaths resulting from large intestinal perforation, Stevens-Johnson syndrome, and unspecified malignant progression. Two treatment-related deaths in the standard therapy arm resulted from malignant progression and pneumonia.

The PD-L1 CPS was 1 or higher in 79% of the patients in the pembrolizumab arm and 77% of the patients in the standard therapy arm.

Compared with patients treated with standard therapy, a reduced HRdeath was noted for patients who received pembrolizumab and had PD-1 expression on their tumors or in the tumor microenvironment as noted by a PD-L1 CPS of 1 or higher (HR, 0.74; 95% CI, 0.58–0.93; nominal P = .0049) or a PD-L1 tumor proportion score of 50% or higher (HR, 0.53; 95% CI, 0.35–0.81; nominal P = .0014).

Health professional · Treatment of Metastatic and Recurrent Hypopharyngeal Cancer / Treatment Options for Metastatic and Recurrent Hypopharyngeal Cancer / Immunotherapy

Nivolumab

Source: Hypopharyngeal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 14, 2025. Captured 2026-09-09.

Nivolumab is a fully human immunoglobulin G4 anti–PD-1 monoclonal antibody.

Evidence (nivolumab combined with ipilimumab in patients who have not previously received systemic therapy):

The CheckMate 651 trial (NCT02741570) evaluated first-line nivolumab plus ipilimumab versus EXTREME (cetuximab, cisplatin/carboplatin, and 5-FU for up to six cycles followed by cetuximab maintenance) in patients with recurrent or metastatic head and neck SCC.[5] The primary end points were OS in all randomly assigned patients and patients with a PD-L1 CPS of 20 or higher. Secondary end points included OS in patients with a PD-L1 CPS of 1 or higher and PFS, objective response rate, and duration of response in all randomly assigned patients and patients with a PD-L1 CPS of 20 or higher. The absence of a survival benefit for immune checkpoint inhibitors in this trial was an unexpected outcome, given the similarity of nivolumab to pembrolizumab in the studies of patients with cisplatin-refractory disease.[4,7] An editorial accompanying the CheckMate 651 trial analyzed some of the factors that may have contributed to a different result. The editorial suggested that survival in the control group, which was longer than that reported in prior studies, may have been impacted by the greater availability of second-line immunotherapy in the control group (46% in CheckMate 651 compared with 25% in the KEYNOTE-048 trial). The authors also suggested that the coadministration of ipilimumab detracted from the activity of nivolumab, as shown in the CheckMate 714 trial.[10]

Sources: CheckMate 651 · 5 · 4 · 7 · 10

The CheckMate 651 trial (NCT02741570) evaluated first-line nivolumab plus ipilimumab versus EXTREME (cetuximab, cisplatin/carboplatin, and 5-FU for up to six cycles followed by cetuximab maintenance) in patients with recurrent or metastatic head and neck SCC.[5] The primary end points were OS in all randomly assigned patients and patients with a PD-L1 CPS of 20 or higher. Secondary end points included OS in patients with a PD-L1 CPS of 1 or higher and PFS, objective response rate, and duration of response in all randomly assigned patients and patients with a PD-L1 CPS of 20 or higher. The absence of a survival benefit for immune checkpoint inhibitors in this trial was an unexpected outcome, given the similarity of nivolumab to pembrolizumab in the studies of patients with cisplatin-refractory disease.[4,7] An editorial accompanying the CheckMate 651 trial analyzed some of the factors that may have contributed to a different result. The editorial suggested that survival in the control group, which was longer than that reported in prior studies, may have been impacted by the greater availability of second-line immunotherapy in the control group (46% in CheckMate 651 compared with 25% in the KEYNOTE-048 trial). The authors also suggested that the coadministration of ipilimumab detracted from the activity of nivolumab, as shown in the CheckMate 714 trial.[10]

Among all randomly assigned patients, there was no statistically significant difference in OS with nivolumab plus ipilimumab versus EXTREME (median OS, 13.9 vs. 13.5 months; HR, 0.95; 97.9% CI, 0.80–1.13; P = .4951). Among patients with a PD-L1 CPS of 20 or higher, there was also no statistically significant OS difference between the two treatments (median OS, 17.6 vs. 14.6 months; HR, 0.78; 97.51% CI, 0.59–1.03; P = .0469).[5][Level of evidence A1]

Sources: 5 · Level of evidence A1

In patients with a CPS of 1 or higher, the median OS was 15.7 months for patients who received nivolumab plus ipilimumab versus 13.2 months for patients who received EXTREME (HR, 0.82; 95% CI, 0.69–0.97).

Among patients with a CPS of 20 or higher, the median PFS was 5.4 months for patients who received nivolumab plus ipilimumab and 7.0 months for patients who received EXTREME. The objective response rate was 34.1% for patients who received nivolumab plus ipilimumab and 36.0% for patients who received EXTREME.

Grade 3 or 4 treatment-related adverse events occurred in 28.2% of patients who received nivolumab plus ipilimumab and 70.7% of patients who received EXTREME.

CheckMate 651 did not meet its primary end points of OS in the randomly assigned or CPS of 20 or higher populations.

CheckMate 714 (NCT02823574), a double-blind phase II trial, evaluated the clinical benefit of first-line nivolumab plus ipilimumab versus nivolumab alone in 425 patients with recurrent or metastatic head and neck SCC.[6] Patients were randomly assigned in a 2:1 ratio to receive either nivolumab (3 mg/kg intravenously [IV] every 2 weeks) plus ipilimumab (1 mg/kg IV every 6 weeks) or nivolumab (3 mg/kg IV every 2 weeks) plus placebo. Treatment continued for up to 2 years or until disease progression, unacceptable toxic effects, or consent withdrawal. The primary end points were objective response rate and duration of response between treatment arms by blinded independent central review in the population with platinum-refractory recurrent or metastatic disease. These were patients who had recurrent disease less than 6 months after completion of platinum-based chemotherapy (adjuvant or neoadjuvant, or as part of multimodal treatment [chemotherapy, surgery, and/or radiation therapy]). Among the 241 patients (56.7%) with platinum-refractory disease, 159 were assigned to receive nivolumab plus ipilimumab and 82 were assigned to receive nivolumab alone. Among the 184 patients (43.3%) with platinum-eligible disease, 123 were assigned to receive nivolumab plus ipilimumab and 61 were assigned to receive nivolumab alone.[6][Level of evidence B3]

Sources: CheckMate 714 · 6 · 6 · Level of evidence B3

CheckMate 714 (NCT02823574), a double-blind phase II trial, evaluated the clinical benefit of first-line nivolumab plus ipilimumab versus nivolumab alone in 425 patients with recurrent or metastatic head and neck SCC.[6] Patients were randomly assigned in a 2:1 ratio to receive either nivolumab (3 mg/kg intravenously [IV] every 2 weeks) plus ipilimumab (1 mg/kg IV every 6 weeks) or nivolumab (3 mg/kg IV every 2 weeks) plus placebo. Treatment continued for up to 2 years or until disease progression, unacceptable toxic effects, or consent withdrawal. The primary end points were objective response rate and duration of response between treatment arms by blinded independent central review in the population with platinum-refractory recurrent or metastatic disease. These were patients who had recurrent disease less than 6 months after completion of platinum-based chemotherapy (adjuvant or neoadjuvant, or as part of multimodal treatment [chemotherapy, surgery, and/or radiation therapy]). Among the 241 patients (56.7%) with platinum-refractory disease, 159 were assigned to receive nivolumab plus ipilimumab and 82 were assigned to receive nivolumab alone. Among the 184 patients (43.3%) with platinum-eligible disease, 123 were assigned to receive nivolumab plus ipilimumab and 61 were assigned to receive nivolumab alone.[6][Level of evidence B3]

At primary database lock, the objective response rate in the population with platinum-refractory disease was 13.2% (95% CI, 8.4%–19.5%) with nivolumab plus ipilimumab and 18.3% (95% CI, 10.6%–28.4%) with nivolumab alone (odds ratio, 0.68; 95.5% CI, 0.33–1.43; P = .29).

The median duration of response was not reached (NR) in the nivolumab-plus-ipilimumab group (95% CI, 11.0 months–NR) and was 11.1 months (95% CI, 4.1–NR) in the nivolumab-alone group. In the population with platinum-eligible disease, the objective response rate was 20.3% (95% CI, 13.6%–28.5%) with nivolumab plus ipilimumab and 29.5% (95% CI, 18.5%–42.6%) with nivolumab alone.

Among the population with platinum-refractory disease, grade 3 or 4 treatment-related adverse events occurred in 25 of 158 patients (15.8%) who received nivolumab plus ipilimumab and in 12 of 82 patients (14.6%) who received nivolumab alone. Among the population with platinum-eligible disease, grade 3 or 4 treatment-related adverse events occurred in 30 of 122 patients (24.6%) who received nivolumab plus ipilimumab and in 8 of 61 patients (13.1%) who received nivolumab alone.

This trial did not meet its primary end point of objective response rate benefit with first-line nivolumab plus ipilimumab versus nivolumab alone in patients with platinum-refractory recurrent or metastatic head and neck SCC.

Evidence (nivolumab after progression on platinum-based treatment):

A phase III open-label trial included 361 patients with recurrent SCC of the head and neck and disease progression within 6 months after platinum-based chemotherapy. Patients were randomly assigned in a 2:1 ratio to receive either nivolumab (at a dose of 3 mg/kg of body weight) every 2 weeks or standard single-agent systemic therapy (methotrexate, docetaxel, or cetuximab). The primary end point was OS.[7]

Sources: 7

A phase III open-label trial included 361 patients with recurrent SCC of the head and neck and disease progression within 6 months after platinum-based chemotherapy. Patients were randomly assigned in a 2:1 ratio to receive either nivolumab (at a dose of 3 mg/kg of body weight) every 2 weeks or standard single-agent systemic therapy (methotrexate, docetaxel, or cetuximab). The primary end point was OS.[7]

The median OS was 7.5 months (95% CI, 5.5–9.1) in the nivolumab group versus 5.1 months (95% CI, 4.0–6.0) in the standard therapy group. OS was statistically significantly longer with nivolumab than with standard therapy (HRdeath, 0.70; 97.73% CI, 0.51–0.96; P = .01). The estimated 1-year survival rate was approximately 19% higher in patients who received nivolumab (36.0%) than in those who received standard therapy (16.6%).[7][Level of evidence A1]

Sources: 7 · Level of evidence A1

There was no statistically significant difference in median PFS between treatment groups. The 6-month PFS rate was 19.7% with nivolumab versus 9.9% with standard therapy.

The response rate was 13.3% in the nivolumab group versus 5.8% in the standard therapy group.

Grade 3 or 4 treatment-related adverse events occurred in 13.1% of the patients in the nivolumab group compared with 35.1% of the patients in the standard therapy group.

Quality-of-life outcomes—including physical, role, and social functioning and pain, sensory, and social contact problems—were stable in the nivolumab group but worse in the standard therapy group. These outcomes were assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (QLQ) Core Module (QLQ-C30) and the Head and Neck Module (QLQ-H&N35).

In the subgroup of patients with a PD-L1 expression level of 1% or higher, the HRdeath among patients treated with nivolumab versus standard therapy was 0.55 (95% CI, 0.36–0.83). In the subgroup of patients with a PD-L1 expression level lower than 1%, the HR was 0.89 (95% CI, 0.54–1.45; P = .17 for interaction).

A randomized, phase III, superiority study in India evaluated the dose of immune checkpoint inhibitors in the setting of palliative care for patients with advanced head and neck cancer. Low-dose IV nivolumab (20 mg every 3 weeks) was added to a triple metronomic chemotherapy regimen of oral methotrexate (9 mg/m2 once weekly), celecoxib (200 mg twice daily), and erlotinib (150 mg once daily). Notably, this nivolumab dose is less than 10% of the dose recommended by the U.S. Food and Drug Administration and the European Medicines Agency. A total of 151 patients were randomly assigned to receive either triple metronomic chemotherapy alone (n = 75) or triple metronomic chemotherapy with nivolumab (n = 76). The primary end point was 1-year OS.[8]Although the control arm in this study cannot be considered standard care, lower doses of immunotherapy appeared to have some benefit in this setting.[11]

Sources: 8 · 11

A randomized, phase III, superiority study in India evaluated the dose of immune checkpoint inhibitors in the setting of palliative care for patients with advanced head and neck cancer. Low-dose IV nivolumab (20 mg every 3 weeks) was added to a triple metronomic chemotherapy regimen of oral methotrexate (9 mg/m2 once weekly), celecoxib (200 mg twice daily), and erlotinib (150 mg once daily). Notably, this nivolumab dose is less than 10% of the dose recommended by the U.S. Food and Drug Administration and the European Medicines Agency. A total of 151 patients were randomly assigned to receive either triple metronomic chemotherapy alone (n = 75) or triple metronomic chemotherapy with nivolumab (n = 76). The primary end point was 1-year OS.[8]Although the control arm in this study cannot be considered standard care, lower doses of immunotherapy appeared to have some benefit in this setting.[11]

The addition of low-dose nivolumab to triple metronomic chemotherapy improved the 1-year OS rate from 16.3% (95% CI, 8.0%–27.4%) to 43.4% (95% CI, 30.8%–55.3%) (HR, 0.545; 95% CI, 0.362–0.820; P = .0036).[8][Level of evidence A1]

Sources: 8 · Level of evidence A1

The median OS was 6.7 months (95% CI, 5.8–8.1) for patients who received triple metronomic chemotherapy alone and 10.1 months (95% CI, 7.4–12.6) for patients who received triple metronomic chemotherapy with nivolumab (P = .0052).

The rate of grade 3 or higher adverse events was 50% for patients who received triple metronomic chemotherapy alone and 46.1% for patients who received triple metronomic chemotherapy with nivolumab (P = .744).

Health professional · Treatment of Metastatic and Recurrent Hypopharyngeal Cancer / Treatment Options for Metastatic and Recurrent Hypopharyngeal Cancer

Posttreatment follow-up for metastatic and recurrent hypopharyngeal cancer

Source: Hypopharyngeal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 14, 2025. Captured 2026-09-09.

These patients should have a careful head and neck examination, looking for recurrence monthly for the first posttreatment year, every 2 months for the second year, every 3 months the third year, and every 6 months thereafter.

For patients · General Information About Hypopharyngeal Cancer

Certain factors affect prognosis (chance of recovery) and treatment options.

Source: Hypopharyngeal Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Prognosis depends on:

Sources: Prognosis

The stage of the cancer (whether it affects part of the hypopharynx, involves the whole hypopharynx, or has spread to other places in the body). Hypopharyngeal cancer is usually detected in later stages because early signs and symptoms rarely occur.

Sources: stage

The patient's age, sex, and general health.

The location of the cancer.

Whether the patient smokes during radiation therapy.

Sources: radiation therapy

Treatment options depend on:

The stage of the cancer.

Keeping the patient's ability to talk, eat, and breathe as normal as possible.

The patient's general health.

Patients who have had hypopharyngeal cancer are at an increased risk of developing a second cancer in the head or neck. Frequent and careful follow-up is important.

Sources: second cancer · follow-up

For patients · Stages of Hypopharyngeal Cancer

After surgery, the stage of the cancer may change and more treatment may be needed.

Source: Hypopharyngeal Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

If the cancer is removed by surgery, a pathologist will examine a sample of the cancer tissue under a microscope. Sometimes, the pathologist’s review results in a change to the stage of the cancer and more treatment is needed after surgery.

Sources: surgery · pathologist · microscope

For patients · Stages of Hypopharyngeal Cancer

Hypopharyngeal cancer can recur (come back) after it has been treated.

Source: Hypopharyngeal Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

The cancer may come back in the hypopharynx or in other parts of the body.

For patients

Treatment Option Overview

Source: Hypopharyngeal Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

For patients · Treatment Option Overview

Key Points

Source: Hypopharyngeal Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

There are different types of treatment for patients with hypopharyngeal cancer.

The following types of treatment are used:

The following types of treatment are used:

Surgery

Radiation therapy

Chemotherapy

Immunotherapy

New types of treatment are being tested in clinical trials.

Treatment for hypopharyngeal cancer may cause side effects.

Patients may want to think about taking part in a clinical trial.

Patients can enter clinical trials before, during, or after starting their cancer treatment.

Follow-up care may be needed.

For patients · Treatment Option Overview

There are different types of treatment for patients with hypopharyngeal cancer.

Source: Hypopharyngeal Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Different types of treatment are available for patients with hypopharyngeal cancer. Some treatments are standard (the currently used treatment), and some are being tested in clinical trials. A treatment clinical trial is a research study meant to help improve current treatments or obtain information on new treatments for patients with cancer. When clinical trials show that a new treatment is better than the standard treatment, the new treatment may become the standard treatment. Patients may want to think about taking part in a clinical trial. Some clinical trials are open only to patients who have not started treatment.

Sources: hypopharyngeal cancer · standard · clinical trials · research study · cancer

For patients · Treatment Option Overview

The following types of treatment are used:

Source: Hypopharyngeal Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

For patients · Treatment Option Overview / The following types of treatment are used:

Surgery

Source: Hypopharyngeal Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Surgery (removing the cancer in an operation) is a common treatment for all stages of hypopharyngeal cancer. The following surgical procedures may be used:

Sources: Surgery · stages

Laryngopharyngectomy: Surgery to remove the larynx (voice box) and part of the pharynx (throat).

Sources: larynx · pharynx

Partial laryngopharyngectomy: Surgery to remove part of the larynx and part of the pharynx. A partial laryngopharyngectomy prevents loss of the voice.

Neck dissection: Surgery to remove lymph nodes and other tissues in the neck.

Sources: Neck dissection · lymph nodes · tissues

After the doctor removes all the cancer that can be seen at the time of the surgery, some patients may be given chemotherapy or radiation therapy after surgery to kill any cancer cells that are left. Treatment given after the surgery, to lower the risk that the cancer will come back, is called adjuvant therapy.

Sources: chemotherapy · radiation therapy · cells · adjuvant therapy

For patients · Treatment Option Overview / The following types of treatment are used:

Radiation therapy

Source: Hypopharyngeal Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Radiation therapy is a cancer treatment that uses high-energy x-rays or other types of radiation to kill cancer cells or keep them from growing. External radiation therapy uses a machine outside the body to send radiation toward the area of the body with cancer.

Sources: x-rays · radiation · External radiation therapy

Radiation therapy may work better in patients who have stopped smoking before beginning treatment. External radiation therapy to the thyroid or the pituitary gland may change the way the thyroid gland works. A blood test to check the thyroid hormone level in the body may be done before and after therapy to make sure the thyroid gland is working properly.

Sources: thyroid · pituitary gland · blood test · thyroid hormone

For patients · Treatment Option Overview / The following types of treatment are used:

Chemotherapy

Source: Hypopharyngeal Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Chemotherapy is a cancer treatment that uses drugs to stop the growth of cancer cells, either by killing the cells or by stopping the cells from dividing. When chemotherapy is taken by mouth or injected into a vein or muscle, the drugs enter the bloodstream and can reach cancer cells throughout the body (systemic chemotherapy).

Sources: drugs · injected · vein · systemic chemotherapy

Chemotherapy may be used to shrink the tumor before surgery or radiation therapy. This is called neoadjuvant chemotherapy.

Sources: tumor · neoadjuvant

For more information, see Drugs Approved for Head and Neck Cancer. (Hypopharyngeal cancer is a type of head and neck cancer.)

Sources: Drugs Approved for Head and Neck Cancer · head and neck cancer

For patients · Treatment Option Overview / The following types of treatment are used:

Immunotherapy

Source: Hypopharyngeal Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Immunotherapy is a treatment that uses a person's immune system to fight cancer. Your doctor may suggest biomarker tests to help predict your response to certain immunotherapy drugs. Learn more about Biomarker Testing for Cancer Treatment.

Sources: Immunotherapy · Biomarker Testing for Cancer Treatment

Pembrolizumab and nivolumab are types of immunotherapy used to treat metastatic or recurrent hypopharyngeal cancer.

Sources: Pembrolizumab · nivolumab · metastatic · recurrent

Learn more about Immunotherapy to Treat Cancer.

Sources: Immunotherapy to Treat Cancer

For patients · Treatment Option Overview

New types of treatment are being tested in clinical trials.

Source: Hypopharyngeal Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Information about clinical trials is available from the NCI website.

Sources: NCI website

For patients · Treatment Option Overview

Treatment for hypopharyngeal cancer may cause side effects.

Source: Hypopharyngeal Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

For information about side effects caused by treatment for cancer, visit our Side Effects page.

Sources: side effects · Side Effects

For patients · Treatment Option Overview

Patients may want to think about taking part in a clinical trial.

Source: Hypopharyngeal Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

For some patients, taking part in a clinical trial may be the best treatment choice. Clinical trials are part of the cancer research process. Clinical trials are done to find out if new cancer treatments are safe and effective or better than the standard treatment.

Sources: clinical trial · standard treatment

Many of today's standard treatments for cancer are based on earlier clinical trials. Patients who take part in a clinical trial may receive the standard treatment or be among the first to receive a new treatment.

Patients who take part in clinical trials also help improve the way cancer will be treated in the future. Even when clinical trials do not lead to effective new treatments, they often answer important questions and help move research forward.

For patients · Treatment Option Overview

Patients can enter clinical trials before, during, or after starting their cancer treatment.

Source: Hypopharyngeal Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Some clinical trials only include patients who have not yet received treatment. Other trials test treatments for patients whose cancer has not gotten better. There are also clinical trials that test new ways to stop cancer from recurring (coming back) or reduce the side effects of cancer treatment.

Sources: side effects

Clinical trials are taking place in many parts of the country. Information about clinical trials supported by NCI can be found on NCI’s clinical trials search webpage. Clinical trials supported by other organizations can be found on the ClinicalTrials.gov website.

Sources: clinical trials search · ClinicalTrials.gov

For patients · Treatment Option Overview

Follow-up care may be needed.

Source: Hypopharyngeal Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

As you go through treatment, you will have follow-up tests or check-ups. Some tests that were done to diagnose or stage the cancer may be repeated to see how well the treatment is working. Decisions about whether to continue, change, or stop treatment may be based on the results of these tests.

Sources: diagnose · stage

Some of the tests will continue to be done from time to time after treatment has ended. The results of these tests can show if your condition has changed or if the cancer has recurred (come back).

For hypopharyngeal cancer, follow-up to check for recurrence should include careful head and neck exams once a month in the first year after treatment ends, every 2 months in the second year, every 3 months in the third year, and every 6 months thereafter.

Sources: recurrence

For patients

Treatment of Stage I Hypopharyngeal Cancer

Source: Hypopharyngeal Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

For information about the treatments listed below, see the Treatment Option Overview section.

Sources: Treatment Option Overview

Treatment of stage I hypopharyngeal cancer may include:

Sources: stage I hypopharyngeal cancer

Laryngopharyngectomy and neck dissection with or without high-dose radiation therapy to the lymph nodes of the neck.

Sources: neck dissection · high-dose radiation · therapy · lymph nodes

Partial laryngopharyngectomy with or without high-dose radiation therapy to the lymph nodes on both sides of the neck.

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

Sources: clinical trial search · General information

For patients

Treatment of Stage II Hypopharyngeal Cancer

Source: Hypopharyngeal Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

For information about the treatments listed below, see the Treatment Option Overview section.

Sources: Treatment Option Overview

Treatment of stage II hypopharyngeal cancer may include:

Sources: stage II hypopharyngeal cancer

Laryngopharyngectomy and neck dissection. High-dose radiation therapy to the lymph nodes of the neck may be given before or after surgery.

Sources: neck dissection · High-dose radiation · therapy · lymph nodes · surgery

Partial laryngopharyngectomy. High-dose radiation therapy to the lymph nodes of the neck may be given before or after surgery.

Chemotherapy given during or after radiation therapy or after surgery.

Sources: Chemotherapy · radiation therapy

A clinical trial of chemotherapy followed by radiation therapy or surgery.

Sources: clinical trial

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

Sources: clinical trial search · General information

For patients

Treatment of Stage III Hypopharyngeal Cancer

Source: Hypopharyngeal Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

For information about the treatments listed below, see the Treatment Option Overview section.

Sources: Treatment Option Overview

Treatment of stage III hypopharyngeal cancer may include:

Sources: stage III hypopharyngeal cancer

Radiation therapy before or after surgery.

Sources: Radiation therapy · surgery

Chemotherapy given during or after radiation therapy or after surgery.

Sources: Chemotherapy

A clinical trial of chemotherapy followed by surgery and/or radiation therapy.

Sources: clinical trial

A clinical trial of surgery followed by chemotherapy given at the same time as radiation therapy.

A clinical trial of chemotherapy given at the same time as radiation therapy.

Treatment and follow-up of stage III hypopharyngeal cancer is complex and is ideally overseen by a team of specialists with experience and expertise in treating this type of cancer. If all or part of the hypopharynx is removed, the patient may need plastic surgery and other special help with breathing, eating, and talking.

Sources: follow-up · specialists · cancer · hypopharynx · plastic surgery

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

Sources: clinical trial search · General information

For patients

Treatment of Stage IV Hypopharyngeal Cancer

Source: Hypopharyngeal Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

For information about the treatments listed below, see the Treatment Option Overview section.

Sources: Treatment Option Overview

Treatment of stages IVA, IVB, and IVC hypopharyngeal cancer that can be treated with surgery may include:

Sources: stages IVA · IVB · IVC hypopharyngeal cancer · surgery

Radiation therapy before or after surgery.

Sources: Radiation therapy

A clinical trial of chemotherapy followed by surgery and/or radiation therapy.

Sources: clinical trial · chemotherapy

A clinical trial of surgery followed by chemotherapy given at the same time as radiation therapy.

Surgical treatment and follow-up of stage IV hypopharyngeal cancer is complex and is ideally overseen by a team of specialists with experience and expertise in treating this type of cancer. If all or part of the hypopharynx is removed, the patient may need plastic surgery and other special help with breathing, eating, and talking.

Sources: follow-up · specialists · cancer · hypopharynx · plastic surgery

Treatment of stages IVA, IVB, and IVC hypopharyngeal cancer that cannot be treated with surgery may include:

Sources: stages IVA · IVB · IVC hypopharyngeal cancer

Radiation therapy.

Chemotherapy given at the same time as radiation therapy.

A clinical trial of radiation therapy with chemotherapy.

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

Sources: clinical trial search · General information

For patients

Treatment of Recurrent and Metastatic Hypopharyngeal Cancer

Source: Hypopharyngeal Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

For information about the treatments listed below, see the Treatment Option Overview section.

Sources: Treatment Option Overview

Treatment of hypopharyngeal cancer that has recurred (come back) or that has spread to other parts of the body may include:

Sources: hypopharyngeal cancer · recurred

Surgery.

Sources: Surgery

Radiation therapy.

Sources: Radiation therapy

Chemotherapy.

Sources: Chemotherapy

Immunotherapy (nivolumab or pembrolizumab).

Sources: Immunotherapy · nivolumab · pembrolizumab

A clinical trial of chemotherapy.

Sources: clinical trial

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

Sources: clinical trial search · General information

Studies

Radiotherapy With Cisplatin Versus Radiotherapy With Cetuximab After Induction Chemotherapy for Larynx Preservation

NCT00169247 · COMPLETED · phase2

Larynx Cancer, Hypopharynx Cancer

ClinicalTrials.gov record

Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and Neck

NCT02113878 · COMPLETED · phase1

Carcinoma, Squamous Cell of Head and Neck, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Hypopharyngeal Cancer, Early Invasive Cervical Squamous Cell Carcinoma, Carcinoma...

ClinicalTrials.gov record

Disease and treatment settings

Hypopharyngeal Cancer

Disease and treatment setting

Hypopharyngeal Cancer

recurrent Hypopharyngeal Cancer

Disease and treatment setting

Treatment of Metastatic and Recurrent Hypopharyngeal Cancer

Stage I Hypopharyngeal Cancer

Disease and treatment setting

Treatment of Stage I Hypopharyngeal Cancer

Stage II Hypopharyngeal Cancer

Disease and treatment setting

Treatment of Stage II Hypopharyngeal Cancer

Stage III Hypopharyngeal Cancer

Disease and treatment setting

Treatment of Stage III Hypopharyngeal Cancer

Stage IV Hypopharyngeal Cancer

Disease and treatment setting

Treatment of Stage IV Hypopharyngeal Cancer

Stage IV Hypopharyngeal Cancer

Disease and treatment setting

Treatment Options for Resectable Stage IV Hypopharyngeal Cancer

Stage IV Hypopharyngeal Cancer

Disease and treatment setting

Treatment Options for Unresectable Stage IV Hypopharyngeal Cancer